The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

GLP-1 agonists and glucose-dependent insulinotropic polypeptide (GIP) agonists currently prescribed ... Polypeptide and/or Glucagon-like Peptide-1 Receptor Agonist Prescriptions and Substance ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...